(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -19.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Novavax's revenue in 2026 is $411,649,000.On average, 10 Wall Street analysts forecast NVAX's revenue for 2026 to be $80,532,646,842, with the lowest NVAX revenue forecast at $65,912,848,645, and the highest NVAX revenue forecast at $100,561,440,355. On average, 10 Wall Street analysts forecast NVAX's revenue for 2027 to be $41,423,861,619, with the lowest NVAX revenue forecast at $25,873,412,611, and the highest NVAX revenue forecast at $58,731,656,573.
In 2028, NVAX is forecast to generate $35,247,574,412 in revenue, with the lowest revenue forecast at $15,756,710,269 and the highest revenue forecast at $64,695,082,159.